Dr. Fraizer Discusses the MaGIC Consortium

Lindsay Frazier, MD
Published: Tuesday, May 29, 2018



Lindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.

MaGIC consists of the world’s leading experts in pediatric oncology, gynecologic oncology, and testicular cancer. Frazier says that all these practitioners are working together to advance the science behind germ cell tumors, and create better clinical trials for patients in these populations. The group has collected past clinical trial data in a common database to analyze and determine what questions should be addressed in future clinical trials, says Fraizer.

One of the first things that MaGIC achieved was reaching a consensus on risk of recurrence. Fraizer says that these various experts were able to have a discussion to clarify what patients are at risk for recurrence, and decide when therapy should be intensified or reduced. In the 8 years that the MaGIC Consortium has been together, they have successfully initiated 3 NCI-funded international clinical trials for patients between the ages of 0 and 50 years.


Lindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.

MaGIC consists of the world’s leading experts in pediatric oncology, gynecologic oncology, and testicular cancer. Frazier says that all these practitioners are working together to advance the science behind germ cell tumors, and create better clinical trials for patients in these populations. The group has collected past clinical trial data in a common database to analyze and determine what questions should be addressed in future clinical trials, says Fraizer.

One of the first things that MaGIC achieved was reaching a consensus on risk of recurrence. Fraizer says that these various experts were able to have a discussion to clarify what patients are at risk for recurrence, and decide when therapy should be intensified or reduced. In the 8 years that the MaGIC Consortium has been together, they have successfully initiated 3 NCI-funded international clinical trials for patients between the ages of 0 and 50 years.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x